BIOTECH CATALYST AI SCANNER — October WK 5
BIOSTOCKINFO / CATALYST SCANNER
Scan date 2026-10-24 · 10 featured · 10 watchlist
The tape
MarketScreener tied the broader market’s weekly decline to oil prices, inflation worries and technology weakness. Biotech had a different week. Gilead agreed to acquire PepStar’s oral inflammation program, while the White House proposed restrictions on U.S.–China biotech deals (Fierce Biotech, Axios). XBI gained 3.6% against a falling S&P benchmark, but remains 11.8% below its August 19 high. This was a rebound within a retreat, not a return to the peak.
The money backdrop remains mixed. S&P Global reported slower business growth alongside accelerating selling prices. Lycia priced its IPO above planned terms, showing an open financing window for at least some developers (Axios). Treasury yields dropped Thursday, according to Kiplinger. The ten-year ended at 4.99%, down 11 basis points this week but up 31 over three months. Rates and financing access determine what small biotech pays to replenish cash.
The rebound has not repaired this list: 16 of the 20 names fell over the past month; the median move was -15.1%, against XBI’s -3.5%. TARA, NKTX and CATX trade below estimated cash. RGNX needs cash within a year of its event; ANNX, RZLT and SVRA also merit funding attention because their runways are shorter. The Federal Reserve’s two-day meeting begins October 27.
This week at a glance
| TICKER | CATALYST | DATE | RANK |
|---|---|---|---|
| SLGL | Topline Data, SGT-610 (patidegib gel, 2%) | late November 2026 | 92 |
| IVA | Topline Data, lanifibranor | in the fourth quarter of this year | 90 |
| ANNX | Topline Data, Vonaprument (formerly ANX007) | fourth quarter of 2026 | 86 |
| BDTX | Interim Data, silevertinib | fourth quarter of 2026 | 86 |
| OCS | Topline Data, Licaminlimab (OCS-02) | around year-end | 86 |
| NRXP | GDUFA, ketamine | Nov 10, 2026 | 85 |
| TARA | Interim Data, choline chloride | in the fourth quarter of this year | 83 |
| ZURA | Topline Data, tibulizumab | Q4 2026 | 83 |
| NKTX | Conference Presentation, NKX019 | Nov 8, 2026 | 82 |
| SNDX | Topline Data, axatilimab | fourth quarter of 2026 | 81 |
Top 10 names by scanner score, highest first. Rank is the scanner’s score out of 100.
Featured
SLGL — Sol-Gel Technologies
CATALYST late November 2026Data readout | RANK 92 | PRICE $69.45 +4% 20d |
| CAP $227M (3M sh) | CASH $44M ~32 mo | |
SGT-610 Phase 3 results in Gorlin syndrome are expected late November 2026 (company's words; week-level precision); ODD, BTD. The primary endpoint counts new facial basal cell carcinomas at month 12, testing whether topical treatment prevents lesions rather than treating existing tumors.
Company. Sol-Gel develops treatments for rare and severe skin diseases, led by topical patidegib. Its broader plans include additional basal cell carcinoma studies and territorial launches of EPSOLAY and TWYNEO through commercial and development partners.
Science & competition. Patidegib blocks the hedgehog growth-signaling pathway in the skin. Gorlin syndrome causes repeated basal cell carcinomas, making prevention a chronic treatment problem. Standard care is individualized surveillance and lesion treatment, chiefly surgery, with topical or systemic therapies used for selected lesions.
Competition sources
Sources: Search Orphan Drug Designations and Approvals · Clinical practice guidelines for the management of basal cell carcinoma in Gorlin syndrome - Journal of the...
Why it could work. Local delivery aims to suppress tumor formation without systemic exposure. Of 113 enrolled patients, 102 completed treatment, supporting the feasibility of sustained twice-daily application.
Why it could fail. The gel may not penetrate deeply enough to suppress emerging tumors. Variable lesion formation can also obscure a treatment effect against inactive vehicle gel.
IVA — Inventiva
CATALYST in the fourth quarter of this yearData readout | RANK 90 | PRICE $3.71 +10% 20d |
| CAP $717M (193M sh) | CASH $237M ~25 mo | |
Lanifibranor’s Phase 3 NATiV3 results in metabolic dysfunction-associated steatohepatitis are expected in the fourth quarter of this year (company's words; quarter-level precision); BTD, FTD. The biopsy-based endpoints assess disease resolution without worsening fibrosis and fibrosis improvement without worsening disease.
Company. Inventiva is a clinical-stage developer of oral small molecules for metabolic dysfunction-associated steatohepatitis, or MASH. Lanifibranor leads the business, with licensing collaborations involving Chia Tai Tianqing and Hepalys and a planned subsequent U.S. NDA submission.
Science & competition. Lanifibranor activates three cellular switches governing metabolism, inflammation and scarring. Rivals include Survodutide (Boehringer Ingelheim, Phase 3) and Efruxifermin (Akero Therapeutics, Phase 3). Standard care includes lifestyle changes, cardiometabolic management and approved resmetirom or semaglutide for eligible patients with moderate-to-advanced fibrosis.
Competition sources
Sources: REZDIFFRA® prescribing information · FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’ | FDA · Study Details | nct06632444 | Patient Clinical Trials website · Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH) · 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026 | D...
Why it could work. The earlier NATIVE trial demonstrated improvements in both MASH and fibrosis. Activating several metabolic pathways gives a biological rationale for addressing inflammation and scarring together.
Why it could fail. Fluid retention and weight gain are established risks of this drug class. Either can complicate long-term treatment in patients already vulnerable to cardiovascular disease.
ANNX — Annexon
CATALYST fourth quarter of 2026Data readout | RANK 86 | PRICE $3.75 +3% 20d |
| CAP $711M (190M sh) | CASH $198M ~12 mo | |
Vonaprument’s Phase 3 ARCHER II geographic atrophy results are expected fourth quarter of 2026 (company's words; quarter-level precision); FTD. The month-15 analysis tests protection against confirmed best corrected visual acuity loss of at least 15 letters, making functional vision the central question.
Company. Annexon develops immunotherapies for neuroinflammatory diseases driven by the classical complement system. Its pipeline includes vonaprument for geographic atrophy and tanruprubart for Guillain-Barre syndrome, with a BLA submission for the latter also expected this quarter.
Science & competition. Injected into the eye, vonaprument blocks C1q, an initiating immune-system protein. Rivals include Pegcetacoplan (Apellis, FDA-approved 2023) and Avacincaptad pegol (Astellas / IVERIC bio, FDA-approved 2023). Standard care includes monitoring and these intravitreal treatments for eligible patients to slow lesion progression.
Competition sources
Sources: DailyMed - SYFOVRE- pegcetacoplan injection, solution · Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary En...
Why it could work. Phase 2 ARCHER showed statistically significant, dose-dependent protection from severe vision loss. Through month 12, there were zero retinal vasculitis events and no increase in abnormal vessel growth versus sham.
Why it could fail. Functional vision measurements are noisy. A larger global trial must reproduce the earlier benefit despite variability in eye-chart results and disease progression.
BDTX — Black Diamond Therapeutics
CATALYST fourth quarter of 2026Data readout | RANK 86 | PRICE $1.88 +0% 20d |
| CAP $108M (57M sh) | CASH $100M ~37 mo | |
Silevertinib’s Phase 2 update in frontline non-classical EGFR-mutant lung cancer is expected fourth quarter of 2026 (company's words; quarter-level precision). Updated response durability and FDA feedback will clarify whether the existing signal supports a practical pivotal development path.
Company. Black Diamond develops oncology drugs targeting families of cancer-driving mutations. Silevertinib leads its lung cancer and glioblastoma programs, while Servier licenses BDTX-4933. A randomized glioblastoma study portion is also planned for initiation this quarter.
Science & competition. Silevertinib blocks mutated epidermal growth factor receptor signaling that drives tumor growth. Rivals include Firmonertinib (ArriVent BioPharma, Phase 3 (ALPACCA)). Afatinib is the established FDA-approved targeted standard for this uncommon-mutation setting; treatment selection depends on the mutation and the patient’s disease.
Competition sources
Sources: AFATINIB TABLETS prescribing information · Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 202...
Why it could work. Earlier results showed an 86% response rate in central nervous system tumors. Brain activity strengthens the rationale for a drug intended to control disease beyond the lung.
Why it could fail. Responses in a small cohort may weaken with follow-up. An expensive randomized pivotal trial or additional dose-optimization requirements would increase development time and resource demands.
Market context. Market capitalization is only slightly above estimated cash, leaving little positive value for the operating business. Trading near the bottom of its annual range adds a skeptical valuation backdrop to a catalyst involving both clinical durability and regulatory feasibility.
OCS — Oculis Holding
CATALYST around year-endData readout | RANK 86 | PRICE $7.90 -15% 20d |
| CAP $537M (68M sh) | CASH $239M ~42 mo | |
Licaminlimab’s PREDICT-1 registrational dry eye results are expected around year-end (company's words; month-level precision). The study tests whether genotype-based patient selection reproduces the earlier treatment signal in a setting intended to support registration.
Company. Oculis develops ophthalmic and neuro-ophthalmic treatments, with programs spanning licaminlimab, OCS-01 for diabetic macular edema and Privosegtor for optic neuropathies. Its broader schedule includes an OCS-01 NDA submission and additional Privosegtor development activity this quarter.
Science & competition. Licaminlimab blocks tumor necrosis factor alpha, an inflammatory signal, using topical eye drops. Rivals include Restasis (Allergan/AbbVie, FDA-approved, 2002) and Cequa (Sun Pharmaceutical, FDA-approved, 2018). Standard care starts with lubricants and trigger management, adding prescription anti-inflammatory therapy when needed.
Competition sources
Sources: Drug Trials Snapshot: TRYPTYR | FDA · EX-99.2 · Dry Eye Disease Drug Pipeline: 49 Assets by Phase – Douglas Insights
Why it could work. Across two Phase 2 trials, carriers of a particular tumor necrosis factor receptor genotype showed five- to seven-fold greater responses than noncarriers. Patient selection is the central biological argument.
Why it could fail. Strong responses to inactive eye drops and variable symptoms can compress the treatment difference. Genetic selection does not eliminate environmental effects or inconsistent signs and symptoms.
Market context. The shares sit in the bottom tenth of their annual range. The setup pairs a depressed trading position with a registrational test of biomarker selection, rather than an immediate cash-shortfall catalyst.
NRXP — NRx Pharmaceuticals
CATALYST Nov 10, 2026Regulatory | RANK 85 | PRICE $2.49 -17% 20d |
| CAP $108M (43M sh) | CASH $41M ~25 mo | |
The FDA’s generic-drug review goal date for preservative-free ketamine is Nov 10, 2026. This ANDA concerns manufacturing and packaging clearance for ketamine’s labeled uses, not approval of the separate depression development program.
Company. NRx develops central nervous system therapies led by preservative-free intravenous ketamine and NRX-101. Its broader business includes clinic activity and development collaborations, while a separate ketamine NDA for depression targets a later regulatory pathway.
Science & competition. Ketamine blocks receptors involved in nerve signaling; this application concerns a preservative-free intravenous formulation. Rivals include KETALAR (Par Health USA, FDA-approved NDA (1970)) and Ketamine HCl injection (Fresenius Kabi, FDA-approved ANDA (2023)). Anesthesia teams individualize care; propofol is commonly used for induction and procedural sedation.
Competition sources
Sources: NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor... · DailyMed - KETAMINE HYDROCHLORIDE injection, solution, concentrate · label (accessdata.fda.gov)
Why it could work. The FDA reclassified the vial-packaging amendment from major to minor. That narrows the immediate execution question, although the change itself is not approval.
Why it could fail. Container integrity or manufacturing deficiencies can still delay clearance. Generic pricing also limits the commercial opportunity, and this ANDA does not authorize depression marketing.
Recent development. On September 29, DARPA awarded NRx Defense an $11.2 million contract, initially obligating $6.7 million, for robotic magnetic stimulation combined with NRX-101 (company announcement). This is non-dilutive support for another program, not evidence resolving ketamine’s packaging review.
Filing flag. FDA initially cited a major deficiency regarding the vial luer-lock component before reclassifying it as minor, delaying target commercial sales from Q3 2026 to after the November 10, 2026 GDUFA date. The company reported a working capital deficit of $17.8 million as of March 31, 2026.
TARA — Protara Therapeutics
CATALYST in the fourth quarter of this yearData readout | RANK 83 | PRICE $2.33 -29% 20d |
| CAP $138M (59M sh) | CASH $141M ~26 mo | |
Intravenous choline chloride’s Phase 2b THRIVE-3 interim results are expected in the fourth quarter of this year (company's words; quarter-level precision). Safety and drug-exposure results will guide dose selection for the randomized Phase 3 portion in choline-deficient patients dependent on intravenous nutritional support.
Company. Protara develops treatments for cancer and rare diseases. Alongside intravenous choline chloride, TARA-002 is being studied in non-muscle invasive bladder cancer and lymphatic malformations, with additional enrollment milestones across those programs expected this quarter.
Science & competition. Choline supports cell membranes and the liver’s transport of fat. Intravenous supplementation replaces a nutrient missing from standard nutritional mixtures. Standard care uses individualized parenteral nutrition and fluids plus specialist intestinal rehabilitation; therapies that reduce nutritional-support requirements do not directly replace deficient choline.
Competition sources
Sources: Search Orphan Drug Designations and Approvals · GI and Hepatology News - Weekly apraglutide cuts parenteral support in phase 3 short bowel syndrome trial · Updates in Intestinal Failure Management - PMC · label (accessdata.fda.gov)
Why it could work. Choline is an essential nutrient with established physiological functions. Predictable exposure and clean safety would support dose selection without requiring this interim cohort to establish long-term clinical benefit.
Why it could fail. Exposure may vary too widely for clear dose selection. Intravenous treatment in medically fragile patients can also produce adverse effects that complicate progression into the pivotal portion.
Market context. The market values the company below estimated cash, assigning the operating business a negative residual value. That creates a distinct mismatch between balance-sheet value and pipeline expectations, but the upcoming readout remains a dosing step rather than definitive pivotal efficacy.
ZURA — Zura Bio
CATALYST Q4 2026Data readout | RANK 83 | PRICE $3.36 -17% 20d |
| CAP $322M (96M sh) | CASH $180M ~28 mo | |
Tibulizumab’s Phase 2 TibuSHIELD results in hidradenitis suppurativa are expected Q4 2026 (company's words; quarter-level precision). This first proof-of-concept readout tests whether blocking two immune pathways produces meaningful clinical activity with acceptable safety.
Company. Zura develops dual-pathway antibodies for autoimmune and inflammatory diseases, led by tibulizumab. Beyond hidradenitis suppurativa, its development plans include systemic sclerosis results and a new Phase 2 study in polymyalgia rheumatica, broadening the same candidate’s clinical reach.
Science & competition. Tibulizumab blocks interleukin-17 and B-cell activating factor, addressing inflammatory signaling and B-cell biology. Rivals include bimekizumab (UCB, FDA-approved, 2024) and lutikizumab (AbbVie, Phase 3 INTREPID). Standard care combines individualized medical and procedural treatment, including biologics such as adalimumab, antibiotics and surgery where appropriate.
Competition sources
Sources: Search Orphan Drug Designations and Approvals · FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa pat... · UCB News UCB Receives U.S. FDA Approval for BIMZE · ISPOR - THE EVOLVING TREATMENT LANDSCAPE OF MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA: APPROVED THERAPIES... · First joint guidelines of care for hidradenitis suppurativa issued by American Academy of Dermatology and H... · AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved... · AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved... · Affibody Announces New Izokibep Data at EADV 2026 Demonstrating Efficacy Across Patient Subgroups and Strin...
Why it could work. Dual blockade targets both cytokine-driven inflammation and B-cell activity. The trial randomized 247 participants, providing a substantial controlled test of the proposed combined mechanism.
Why it could fail. Placebo responses in this disease run high: AbbVie’s lutikizumab cleared its Phase 3 on October 22 with 31.4% versus 23.4% on placebo (AbbVie). Extra B-cell suppression may add infection risk without enough benefit.
Market context. Shares trade in the bottom tenth of their annual range. At 1.78 times estimated cash, market capitalization still assigns positive value to the operating business despite that weak trading position.
NKTX — Nkarta
CATALYST Nov 8, 2026Conference | RANK 82 | PRICE $1.79 -35% 20d |
| CAP $128M (72M sh) | CASH $214M ~28 mo | |
NKX019’s preliminary Phase 1/2 idiopathic inflammatory myopathy results will be presented on Nov 8, 2026. The presentation covers safety, cell activity and early clinical outcomes, testing whether B-cell depletion accompanies meaningful improvement in autoimmune muscle disease.
Company. Nkarta develops donor-derived, off-the-shelf natural killer cell therapies. NKX019 leads its autoimmune pipeline across inflammatory myopathy, systemic sclerosis and lupus nephritis, with additional systemic sclerosis and pooled safety presentations scheduled after the featured muscle-disease presentation.
Science & competition. NKX019 uses engineered donor natural killer cells to target CD19-bearing B cells. Rivals include efgartigimod (argenx, Phase 3 ALKIVIA) and anifrolumab (AstraZeneca, Phase 3 in IIM). Efgartigimod met its Phase 3 primary endpoint on August 17, with a week-52 Total Improvement Score of 47.95 versus 32.56 on placebo (argenx). Standard care uses glucocorticoids, steroid-sparing immunosuppressants and selected use of intravenous immunoglobulin.
Competition sources
Sources: Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review - PMC · argenx Announces Positive Topline Results from Phase 3
Why it could work. Deep B-cell depletion occurred in all previously reported patients receiving the fuller conditioning regimen. Off-the-shelf cells avoid patient-specific manufacturing, while the new presentation tests clinical relevance in muscle disease.
Why it could fail. Donor cells may not persist long enough for durable disease control. Intensive conditioning adds infection and blood-cell toxicity risks that matter especially in non-cancer treatment.
Market context. Estimated cash exceeds market capitalization by about $86 million. The market therefore assigns a substantial negative residual value to operations before the first myopathy results. Cash backing and clinical validation are separate questions: early depletion must still translate into functional benefit.
SNDX — Syndax Pharmaceuticals
CATALYST fourth quarter of 2026Data readout | RANK 81 | PRICE $13.40 -26% 20d |
| CAP $1.2B (89M sh) | CASH $505M ~27 mo | |
Axatilimab’s Phase 2 results in newly diagnosed chronic graft-versus-host disease are expected fourth quarter of 2026 (company's words; quarter-level precision). The open-label randomized study combines axatilimab with ruxolitinib, testing earlier treatment use rather than repeating the established later-line setting.
Company. Syndax is a commercial-stage company selling Revuforj and co-commercializing Niktimvo with Incyte. Its development work spans cancer and fibrotic diseases, while the featured axatilimab study examines expansion into newly diagnosed chronic graft-versus-host disease patients.
Science & competition. Axatilimab blocks colony-stimulating factor-1 receptor, reducing inflammatory monocytes and macrophages involved in tissue scarring. Chronic graft-versus-host disease follows donor immune cells attacking recipient organs. Standard first-line care generally uses systemic corticosteroids; ruxolitinib is established after an inadequate response and is a combination partner here.
Competition sources
Sources: Chronic graft-versus-host disease: Update on pathobiology, biomarkers, and evolving treatment algorithms · FDA approves axatilimab-csfr for chronic graft-versus-host disease | FDA
Why it could work. Axatilimab already has a validated role in later-line disease. Earlier macrophage-directed treatment has a biological rationale before extensive tissue scarring becomes established.
Why it could fail. Additional immune suppression can increase infections and overlapping toxicity. Modest incremental benefit would weaken the rationale for bringing a combination regimen into earlier treatment.
Recent development. On October 12, Syndax reported that MAXPIRe missed its primary endpoint and ended further axatilimab development in idiopathic pulmonary fibrosis (company announcement). That closes a different indication; it does not answer whether the chronic graft-versus-host disease combination succeeds.
Filing flag. On October 12, 2026, Syndax announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint.
Watchlist
RZLT — Rezolute
CATALYST mid-December 2026Data readout | RANK 81 |
| PRICE $3.85 -1% 20d | CAP $373M (97M sh) |
Cash $84M, ~14 mo
BTDPhase 3 upLIFT results for ersodetug in tumor hyperinsulinism are expected mid-December 2026 (company's words; month-level precision). Seven of the first eight participants met the glucose-infusion responder criterion and discontinued intravenous glucose. The small, uncontrolled study remains the central evidence limitation, while limited runway keeps subsequent financing relevant.
ACRS — Aclaris Therapeutics
CATALYST Fourth Quarter 2026Data readout | RANK 80 |
| PRICE $3.75 -27% 20d | CAP $552M (147M sh) |
Cash $191M, ~37 mo
Bosakitug’s placebo-controlled Phase 2 atopic dermatitis results are expected Fourth Quarter 2026 (company's words; quarter-level precision). The primary endpoint measures percentage change in Eczema Area and Severity Index at week 24, advancing beyond earlier single-arm evidence. Shares substantially underperformed XBI over the past month, putting controlled efficacy validation against a weakened stock setup.
ENTA — Enanta Pharmaceuticals
CATALYST fourth quarter of 2026Data readout | RANK 80 |
| PRICE $11.64 -2% 20d | CAP $339M (29M sh) |
Cash $200M, ~68 mo
financing filed since the cash date Filing warningEDP-978’s Phase 1 results are expected fourth quarter of 2026 (company's words; quarter-level precision), testing the oral candidate intended for chronic urticaria. Serum tryptase reduction is the key biological-activity signal in healthy volunteers, not evidence of symptom relief in patients. A financing was filed after the cash figure’s date; the readout is an early development test.
Filing flag. In June 2026, the U.S. Court of Appeals for the Federal Circuit affirmed summary judgment against Enanta in its patent litigation against Pfizer, ruling claims of U.S. Patent No. 11,358,953 invalid.
VIR — Vir Biotechnology
CATALYST in the fourth quarter of 2026Data readout | RANK 80 |
| PRICE $10.57 -1% 20d | CAP $1.8B (169M sh) |
Cash $946M, ~56 mo
financing filed since the cash dateElebsiran and tobevibart’s Phase 3 ECLIPSE 1 results in chronic hepatitis delta are expected in the fourth quarter of 2026 (company's words; quarter-level precision). Earlier Phase 2 results showed undetectable viral RNA in 88% of combination-treated participants at week 96. A financing was filed after the cash figure’s date, and the pivotal trial must establish its own outcome.
PHAT — Phathom Pharmaceuticals
CATALYST fourth quarter of 2026Data readout | RANK 79 |
| PRICE $5.74 -21% 20d | CAP $464M (81M sh) |
Cash $171M, ~56 mo
VOQUEZNA’s Phase 2 eosinophilic esophagitis results are expected fourth quarter of 2026 (company's words; quarter-level precision). The blinded treatment portion compares daily treatment with placebo over 12 weeks, testing another use for an existing commercial product. Shares sit in the bottom tenth of their annual range despite the company’s stated expectation of avoiding additional financing.
LXEO — Lexeo Therapeutics
CATALYST Q4 2026Data readout | RANK 78 |
| PRICE $2.80 -15% 20d | CAP $230M (82M sh) |
Cash $220M, ~30 mo
financing filed since the cash dateODD FTDLX2020’s HEROIC PKP2 high-dose update is expected Q4 2026 (company's words; quarter-level precision), covering 12-month follow-up in inherited arrhythmogenic cardiomyopathy. Earlier biopsies showed dose-dependent protein expression, alongside reduced mean arrhythmia burden in high-dose participants. Market value is close to estimated cash, but a financing was filed after the cash figure’s date.
CATX — Perspective Therapeutics
CATALYST Nov 20, 2026Conference | RANK 78 |
| PRICE $1.61 -36% 20d | CAP $184M (114M sh) |
Cash $207M, ~27 mo
Additional bamzireotide navoxetan Phase 1/2a neuroendocrine tumor data are scheduled for Nov 20, 2026. The higher-dose cohort previously showed a 50% objective response rate; confirmation and durability matter ahead of planned pivotal development. Market capitalization remains below estimated cash, assigning a negative residual value to the business despite ongoing clinical and manufacturing commitments.
SVRA — Savara
CATALYST Nov 22, 2026Regulatory | RANK 78 |
| PRICE $4.22 -16% 20d | CAP $867M (206M sh) |
Cash $138M, ~15 mo
ODD FTD BTD Priority Review Filing warningMOLBREEVI’s BLA PDUFA date in autoimmune pulmonary alveolar proteinosis is Nov 22, 2026, following a three-month extension for a major amendment. The application rests on Phase 3 IMPALA-2 and carries ODD, FTD, BTD and Priority Review. This is a regulatory execution test after clinical development, with a shorter runway making further review delays financially relevant.
Filing flag. PDUFA target action date delayed by three months to November 22, 2026, after FDA determined company responses to information requests constituted a major amendment to the BLA.
RGNX — REGENXBIO
CATALYST the fourth quarterData readout | RANK 78 |
| PRICE $6.68 -10% 20d | CAP $441M (66M sh) |
Cash $235M, ~11 mo
financing filed since the cash date Filing warningSurabgene lomparvovec’s pivotal wet age-related macular degeneration results are expected the fourth quarter (company's words; quarter-level precision), alongside partner AbbVie. Earlier follow-up showed sustained vision and reduced injection burden; the separate RGX-121 program remains on clinical hold. Estimated runway ends within a year of the event, and financing was filed after the cash figure’s date.
Filing flag. The FDA placed a clinical hold on partner program RGX-121 in August 2026 following asymptomatic spine MRI findings in five participants, halting the planned BLA resubmission in the near term.
ZBIO — Zenas BioPharma
CATALYST 4Q 2026Data readout | RANK 77 |
| PRICE $26.87 -0% 20d | CAP $1.8B (65M sh) |
Cash $602M, ~32 mo
Filing warningObexelimab’s Phase 2 SunStone lupus results are expected 4Q 2026 (company's words; quarter-level precision), after slipping from earlier midyear guidance. Overall and biomarker-defined results will test whether activity supports a potential Phase 3 program. The stock has held up better than XBI over the past month, contrasting with the widespread weakness elsewhere on this list.
Filing flag. In 2025 filings, Zenas expected to complete enrollment in the Phase 2 SunStone trial around year-end 2025 and report topline results in mid-2026. Topline results timing was subsequently delayed to the fourth quarter of 2026.
The Take
XBI’s weekly rebound leaves this issue’s median monthly decline far deeper than the sector’s, so the relevant distinctions sit below the index. TARA, NKTX and CATX pair negative residual business values with very different evidence tests: dose selection, initial autoimmune activity and tumor-response durability. Cash backing does not make those events equivalent. BDTX sits close to cash value too, but its update also decides how demanding the pivotal development path becomes. RGNX combines pivotal vision data with cash needed within a year of the event, making financing inseparable from the clinical assessment. NRXP and SVRA instead face regulatory execution after packaging or review amendments, not fresh efficacy readouts. The clearest valuation-versus-evidence contrasts are NKTX’s substantial cash discount before first myopathy results and TARA’s below-cash value before a dosing milestone. Neither setup removes the need to distinguish biological activity from a registration-ready outcome.
How the scanner ranks names, estimates cash and reads dates is explained in the methodology note. Companies' own words and SEC filings are the only source for every date above; rivals are named from a cited web search. Not investment advice.
Disclaimer
For information and education only; not investment advice or a recommendation to buy or sell any security. This AI-assisted newsletter may contain errors or omissions, and catalyst dates can change. Verify details against original sources and do your own research. Biotechnology investing involves substantial risk, including loss of capital.
